H6H
NBIX icon

Hightower 6M Holding’s Neurocrine Biosciences NBIX Stock Holding History

Hightower 6M Holding’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,573
Closed -$251K – 319
2022
Q2 		$251K Sell
2,573
-3
-0.1% -$277 0.02% 202
2022
Q1 		$242K Buy
+2,576
New +$218K 0.02% 223

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hightower 6M Holding's NBIX Position: Q3 2022 in Review

Hightower 6M Holding sold out of Neurocrine Biosciences (NBIX) in Q3 2022, closing a stake of 2,573 shares — an estimated $251K sold.

Hightower 6M Holding first reported a position in NBIX in Q1 2022 and held it in 2 quarters. The position peaked at $251K in Q2 2022. 467 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

  • Hightower 6M Holding reported no remaining Neurocrine Biosciences position as of Q3 2022 after selling out during the quarter.
  • Hightower 6M Holding sold 2,573 Neurocrine Biosciences shares in Q3 2022, an estimated $251K.
  • Hightower 6M Holding first reported a position in Neurocrine Biosciences in Q1 2022 and held it in 2 quarters.
  • Hightower 6M Holding's Neurocrine Biosciences position peaked at $251K in Q2 2022.
  • 467 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Hightower 6M Holding's 13F filing for Q3 2022, filed 25 Oct 2022.